RedHill Biopharma (RDHL) Return on Sales (2012 - 2023)

RedHill Biopharma (RDHL) has 11 years of Return on Sales data on file, last reported at 0.45% in Q2 2023.

• Return on Sales for Q2 2023 came in at 0.45%, up 44.0% year-over-year; the trailing twelve-month figure through Jun 2023 was 0.01% (up 1.0% YoY), and the FY2025 annual result was 0.27%, up 28.0% from the prior year.
• Return on Sales grew to 0.45% in Q2 2023 per RDHL's latest filing, from 0.02% in the prior quarter.
• Over five years, Return on Sales peaked at 0.45% in Q2 2023 and troughed at 0.07% in Q4 2021.
• A 5-year average of 0.04% and a median of 0.01% in 2020 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2021 and 2023: Return on Sales decreased 15 bps in 2021, then soared 44 bps in 2023.
• A 5-year view of Return on Sales shows it stood at 0.07% in 2019, then plunged by 90 bps to 0.01% in 2020, then sank by 1032 bps to 0.07% in 2021, then grew by 7 bps to 0.06% in 2022, then jumped by 833 bps to 0.45% in 2023.
• Business Quant data shows RDHL's Return on Sales at 0.45% in Q2 2023, 0.02% in Q1 2023, and 0.06% in Q4 2022.